Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 723 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Normal Saline Solution 0.9% Clear all
Withdrawn Not applicable Interventional

Early Goal Directed Therapy in Sepsis by Emergency Medical Services

NCT02266654
View directory record Official record
Conditions
Sepsis
Interventions
IV fluids, Hospital Notification
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
17 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 16, 2017 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Results available

Adaptive COVID-19 Treatment Trial 3 (ACTT-3)

NCT04492475
View directory record Official record
Conditions
COVID-19
Interventions
Interferon beta-1a, Placebo, Remdesivir
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
55
States / cities
Birmingham, Alabama • Fresno, California • La Jolla, California + 45 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2022 · Synced Sep 18, 2026, 9:29 AM EDT
Terminated Phase 3 Interventional Results available

A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

NCT02377466
View directory record Official record
Conditions
Obstetric Labour, Premature
Interventions
Retosiban IV infusion, Placebo IV infusion
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 45 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
33
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Results available

Transverse Abdominis Plane (TAP) Block After Cesarean Delivery

NCT01170702
View directory record Official record
Conditions
Postoperative Pain, Pregnancy, Obesity
Interventions
0.9% Normal Saline, 0.2% Ropivacaine, 0.5% Ropivacaine, 0.75% Ropivacaine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Sep 18, 2026, 9:29 AM EDT
Recruiting Phase 4 Interventional

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

NCT05267886
View directory record Official record
Conditions
Shock, Cardiogenic
Interventions
Dobutamine, Milrinone, Normal Saline
Drug
Lead sponsor
Ottawa Heart Institute Research Corporation
Other
Eligibility
18 Years and older
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 18, 2026, 9:29 AM EDT
Withdrawn Phase 4 Interventional

Ketamine vs. Placebo as Adjunctive Therapies for Severe Alcohol Withdrawal

NCT02823977
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
Ketamine, Dexmedetomidine, Normal saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2018 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

Fluid Chloride and AKI in Cardiopulmonary Bypass

NCT02668952
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
0.9% Normal Saline (0.9% Sodium Chloride) injection, Isolyte S injection
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 13, 2018 · Synced Sep 18, 2026, 9:29 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline

NCT05109000
View directory record Official record
Conditions
Injection Site Irritation, Injection Site Bruising, Injection Site Discomfort, Benzoic Acid Adverse Reaction, Anesthesia, Local
Interventions
Sodium Chloride 0.9% Inj, Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)
Drug
Lead sponsor
Jeffrey Alan Klein, MD
Industry
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Juan Capistrano, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 18, 2026, 9:29 AM EDT
Recruiting Phase 2 Interventional

Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites

NCT06812390
View directory record Official record
Conditions
Cirrhosis, Ascites Hepatic
Interventions
Albumin infusion (25% albumin), Normal Saline (0.9% NaCl)
Drug
Lead sponsor
Anahita Rabiee MD MHS
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Sep 18, 2026, 9:29 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

NCT04504825
View directory record Official record
Conditions
AL Amyloidosis
Interventions
CAEL-101, Placebo, cyclophosphamide, bortezomib, and Dexamethasone (CyBorD) regimen
Drug · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
26
States / cities
Duarte, California • Palo Alto, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Brain Ketone Metabolism in Type 1 Diabetes

NCT02471040
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Beta-hydroxybutyrate, Normal Saline
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

NCT02325050
View directory record Official record
Conditions
Healthy
Interventions
MVA-BN-Filo, Ad26. ZEBOV, Placebo
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2018 · Synced Sep 18, 2026, 9:29 AM EDT
Recruiting Early Phase 1 Interventional

Intravesical Lactobacillus Crispatus: Clinical Safety and Microbiome Evaluation

NCT07308808
View directory record Official record
Conditions
Spinal Cord Injuries (SCI), Neurogenic Bladder, Urinary Tract Infection (Diagnosis)
Interventions
Lactobacillus Crispatus, Saline bladder wash
Drug · Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Regional Anesthesia (Supra-Orbital and Infra-Orbital Nerve Block) (SION) for Pain Management in Trans-sphenoidal Hypophysectomy

NCT04670614
View directory record Official record
Conditions
Post-operative Surgical Pain
Interventions
Nerve Block with ropivicaine 0.5% Injectable Solution, Nerve Block with Placebo sham control of 0.9% Normal Saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

EXPAREL for Minimally Invasive Supracervical Hysterectomies

NCT03769714
View directory record Official record
Conditions
Pain
Interventions
Saline Solution for Injection, Exparel
Drug
Lead sponsor
Maimonides Medical Center
Other
Eligibility
35 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus

NCT02609789
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Healthy
Interventions
JNJ-55920839, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
3
States / cities
Birmingham, Alabama • Rochester, Minnesota • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 18, 2026, 9:29 AM EDT
Active, not recruiting Phase 2 Interventional

Efficacy of Amicar for Children Having Craniofacial Surgery

NCT02229968
View directory record Official record
Conditions
Craniosynostosis
Interventions
Amicar (ε-aminocaproic acid), normal saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Months to 36 Months
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy

NCT01843504
View directory record Official record
Conditions
Chronic Patellar Tendinopathy, Chronic PT
Interventions
platelet rich plasma, saline
Biological · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 18, 2026, 9:29 AM EDT
Recruiting Phase 4 Interventional

Post-procedural Pain Associated With 5 Versus 20 Intravesical Injections of Onabotulinumtoxin A

NCT04305743
View directory record Official record
Conditions
Urinary Bladder, Overactive, Incontinence, Urge, Incontinence, Urinary, Urinary Urge Incontinence, Urinary Frequency More Than Once at Night, Nocturia
Interventions
OnabotulinumtoxinA 100 UNT
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2020 · Synced Sep 18, 2026, 9:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEF

NCT03541603
View directory record Official record
Conditions
Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction
Interventions
Levosimendan, Matching Placebo
Drug
Lead sponsor
Tenax Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
16
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)

NCT02597127
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia, Diabetes
Interventions
ALN-PCSSC, Normal Saline
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years to 99 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Sep 18, 2026, 9:29 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

PeriOperative ISchemic Evaluation-3 Trial

NCT03505723
View directory record Official record
Conditions
Perioperative Bleeding, Venous Thrombosis, Arterial Thrombosis
Interventions
Tranexamic Acid, Placebo (Saline), Perioperative hypotension-avoidance strategy, Perioperative hypertension-avoidance strategy
Drug · Other
Lead sponsor
Population Health Research Institute
Other
Eligibility
45 Years and older
Enrollment
9,535 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
12
States / cities
New Haven, Connecticut • Weston, Florida • New York, New York + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 18, 2026, 9:29 AM EDT